FDA grants Opdivo combo Breakthrough Designation for melanoma
admin 2nd August 2019 Uncategorised 0Bempegaldesleukin, Nektar’s lead immuno-oncology candidate, is an investigational CD122-preferential IL-2 pathway agonist.
More: FDA grants Opdivo combo Breakthrough Designation for melanoma
Source: News
